Home
About Us
Company Profile
HIstory
Culture
Honor
Products
Cardiovascular series
Psychiatry series
Hepatobiliary, Gastroenterology Series
Respiratory series
Anti-infective virus series
Other series
Large Infusion Series
Huabao Tong Series
Active Pharmaceutical Ingredient Series
R&D
Academician Expert Workstation
Medical Research and Industry Alliance
News
General News
Party group dynamics
Employee activity
HR
Talent Strategy
Company recruitment
Contact us
中文版
2021/03/01
Wenling's First! Wanbande Pharmaceutical Selected as a National-Level Model Academician & Expert Workstation
The Clinical Positioning Expert Workshop on Huperzine A Injection Successfully Held
Congratulations on the successful convening of the National Clinical Pathways Implementation and Management Forum 2018!
Wanbande Pharmaceutical’s two production lines have passed GMP certification.
Accelerate the construction of the Wenling China-Africa Medical Science and Technology Park—both by going global and by actively attracting investment and expertise.
Wanbangde Pharmaceutical R&D Center Building Successfully Tops Out
Deputy Director Xia Jiancheng from the Provincial Administration for Industry and Commerce conducts an in-depth inspection of enterprises.
An invention patent has been authorized by the National Intellectual Property Administration.
Wanbangde Pharmaceutical Group Co., Ltd. Announces Public Disclosure of the Environmental Impact Assessment for a New Project Producing 609 kg of Phloroglucinol Dihydrate Intermediate Annually
The unique advantages of Shuguang Holy Land's Ginkgo Leaf Droplets spark lively discussions among experts and scholars.
Wanbande Group's South African development strategy receives praise from the Provincial Party Secretary.
The Alzheimer's disease drug huperzine A controlled-release tablet has been approved to enter clinical trials.
Wanbangde Pharmaceutical GMP Knowledge Competition Concludes
Public Notice of the Environmental Impact Assessment for the R&D Center Incubator Workshop Project of Wanbangde Pharmaceutical Group Co., Ltd.
Wanbangde Pharmaceutical Group Co., Ltd. Announces Public Disclosure of the Environmental Impact Assessment for Its New Technical Renovation Project, which will add annual production capacity for 20 tons of Bifendate API, 980 tons of Norfloxacin API, and 10 tons of Traditional Chinese Medicine Extracts.
